Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms by Site 3 Neoplasms 3 Neoplasms, Glandular and Epithelial 2 Neoplasms by Histologic Type 2 Digestive System Neoplasms 2 Digestive System Diseases 2 Colorectal Neoplasms 2 Thoracic Neoplasms 1 Stomach Neoplasms 1 Respiratory Tract Neoplasms 1 Rectal Diseases 1 Previously Treated Metastatic Colorectal Cancer 1 Pancreatic Neoplasms 1 Pancreatic Diseases 1 Lung Neoplasms 1 Intestinal Neoplasms 1 Intestinal Diseases 1 Gastrointestinal Neoplasms 1 Gastrointestinal Diseases 1 Endocrine System Diseases 1 Endocrine Gland Neoplasms 1 Colonic Diseases 1 Carcinoma, Pancreatic Ductal 1 Carcinoma, Non-Small-Cell Lung 1 Bronchial Neoplasms 1 Adenocarcinoma 1

Interventions

Oxaliplatin 56 Capecitabine 49 Fluorouracil 37 Cisplatin 37 S 1 (combination) 23 Paclitaxel 18 Docetaxel 18 Leucovorin 16 pembrolizumab 13 Irinotecan 12 apatinib 11 titanium silicide 9 XELOX 9 Trastuzumab 9 Nivolumab 9 Hyperthermic Intraperitoneal Chemotherapy 8 Epirubicin 8 Drug Therapy 8 Tegafur 7 Radiotherapy 6 Neoadjuvant Therapy 6 gimeracil 5 Surgical Procedures, Operative 5 Gastrectomy 5 Chemotherapy, Adjuvant 5 tislelizumab 4 S-1 plus cisplatin 4 Ramucirumab 4 zolbetuximab 3 sintilimab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Stomach Neoplasms × napabucasin × Clear all

NCT02178956 2023-11-15

BRIGHTER

Sumitomo Pharma America, Inc.

Phase 3 Completed

714 enrolled 16 charts

Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡